100 Clinical Results associated with L-Leucine/L-Isoleucine/L-Valine/L-Lysine Acetate/L-Threonine/L-Tryptophan/L-Methionine/L-Cysteine/L-Phenylalanine/L-Tyrosine/L-Arginine/L-Histidine/L-Alanine/L-Proline/L-Serine/L-Aspartic Acid/L-Glutamic Acid

100 Translational Medicine associated with L-Leucine/L-Isoleucine/L-Valine/L-Lysine Acetate/L-Threonine/L-Tryptophan/L-Methionine/L-Cysteine/L-Phenylalanine/L-Tyrosine/L-Arginine/L-Histidine/L-Alanine/L-Proline/L-Serine/L-Aspartic Acid/L-Glutamic Acid

100 Patents (Medical) associated with L-Leucine/L-Isoleucine/L-Valine/L-Lysine Acetate/L-Threonine/L-Tryptophan/L-Methionine/L-Cysteine/L-Phenylalanine/L-Tyrosine/L-Arginine/L-Histidine/L-Alanine/L-Proline/L-Serine/L-Aspartic Acid/L-Glutamic Acid

Literatures (Medical) associated with L-Leucine/L-Isoleucine/L-Valine/L-Lysine Acetate/L-Threonine/L-Tryptophan/L-Methionine/L-Cysteine/L-Phenylalanine/L-Tyrosine/L-Arginine/L-Histidine/L-Alanine/L-Proline/L-Serine/L-Aspartic Acid/L-Glutamic Acid

01 Oct 2021·Bioactive MaterialsQ1 · MATERIALS SCIENCE

l-cysteine-modified chiral gold nanoparticles promote periodontal tissue regeneration

Q1 · MATERIALS SCIENCE

ArticleOA

Author: Yan, Fuhua ; Zhang, Yangheng ; Xiao, Yin ; Zhang, Shuang ; Wang, Zezheng ; Kong, Na ; Yang, Wenrong ; Fu, Huangmei ; Zhou, Hong

Gold nanoparticles (AuNPs) with surface-anchored molecules present tremendous potential in tissue regeneration. However, little is known about chiral-modified AuNPs. In this study, we successfully prepared L/D-cysteine-anchored AuNPs (L/D-Cys-AuNPs) and studied the effects of chiral-modified AuNPs on osteogenic differentiation and autophagy of human periodontal ligament cells (hPDLCs) and periodontal tissue regeneration. In vitro, more L-Cys-AuNPs than D-Cys-AuNPs tend to internalize in hPDLCs. L-Cys-AuNPs also significantly increased the expression of alkaline phosphatase, collagen type 1, osteocalcin, runt-related transcription factor 2, and microtubule-associated protein light chain 3 II and decreased the expression of sequestosome 1 in hPDLCs compared to the expression levels in the hPDLCs treated by D-Cys-AuNPs. In vivo tests in a rat periodontal-defect model showed that L-Cys-AuNPs had the greatest effect on periodontal-tissue regeneration. The activation of autophagy in L-Cys-AuNP-treated hPDLCs may be responsible for the cell differentiation and tissue regeneration. Therefore, compared to D-Cys-AuNPs, L-Cys-AuNPs show a better performance in cellular internalization, regulation of autophagy, cell osteogenic differentiation, and periodontal tissue regeneration. This demonstrates the immense potential of L-Cys-AuNPs for periodontal regeneration and provides a new insight into chirally modified bioactive nanomaterials.

01 Sep 2017·Drugs in R&DQ4 · MEDICINE

Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus

Q4 · MEDICINE

ArticleOA

Author: Takahashi, Yasuo ; Nakayama, Tomohiro ; Tezuka, Kotoe ; Nishida, Yayoi ; Asai, Satoshi ; Takeuchi, Satoshi

BACKGROUNDWe conducted a retrospective cohort study to evaluate and compare the longitudinal effect of monotherapy with L-, L/T-, L/N-, and L/N/T-type calcium channel blockers (CCBs) on estimated glomerular filtration rate (eGFR), and to investigate the association of treatment duration with eGFR in diabetic patients with hypertension.METHODSUsing a clinical database, we identified new users of five CCBs, i.e. amlodipine (L-type, n = 693), nifedipine (L-type, n = 189), azelnidipine (L/T-type, n = 91), benidipine (L/N/T-type, n = 183), and cilnidipine (L/N-type, n = 61). We used a multivariable regression model to evaluate and compare the effects of these drugs on eGFR and serum creatinine, up to 12 months after initiation of study drug administration.RESULTSThere was no significant association between treatment duration and both eGFR and serum creatinine level with all CCB types. In addition, there was no significant difference in mean change in eGFR among the five CCBs, with any treatment duration.CONCLUSIONSOur findings suggest that monotherapy with an L-, L/T-, L/N/T-, or L/N-type CCB may have little influence on renal function parameters and may be safely used in hypertensive patients with diabetes.

100 Deals associated with L-Leucine/L-Isoleucine/L-Valine/L-Lysine Acetate/L-Threonine/L-Tryptophan/L-Methionine/L-Cysteine/L-Phenylalanine/L-Tyrosine/L-Arginine/L-Histidine/L-Alanine/L-Proline/L-Serine/L-Aspartic Acid/L-Glutamic Acid

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Malnutrition	CA	Fresenius Kabi Canada Ltd.	30 Dec 2020
Hypoproteinemia	JP	Otsuka Pharmaceutical Factory, Inc.	03 Apr 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

L-Leucine/L-Isoleucine/L-Valine/L-Lysine Acetate/L-Threonine/L-Tryptophan/L-Methionine/L-Cysteine/L-Phenylalanine/L-Tyrosine/L-Arginine/L-Histidine/L-Alanine/L-Proline/L-Serine/L-Aspartic Acid/L-Glutamic Acid

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation